Company intelligence / Profile preview

Snipe Medical

Ownership: Private
Development stage: Preclinical

Overview

Snipe Medical is developing a minimally invasive, endobronchial ablation device for the treatment of lung cancer. The technology uses irreversible electroporation to achieve precise, nonthermal tumor destruction, aiming to offer a safer and more effective alternative to traditional therapies. No published clinical results as of June 2025; preclinical or early feasibility work is ongoing.

Therapeutic areas: Oncology
Modalities: DeviceIrreversible electroporation (IRE) ablation deviceMinimally invasive endobronchial ablation device
Industry: Therapeutic Medical Devices

Partnerships

Peregrine VenturesShaare Zedek - Arieli Healthcare Innovation Hub (investors/partners)

Beyond the preview

Go deeper on Snipe Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Snipe Medical.

Explore the full profile